News &amp; Updates

Long-term use of aspirin tends to increase the risk of heart failure (HF) in individuals without cardiovascular disease (CVD), suggests a recent study.

Long-term aspirin use may raise HF incidence

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

Administering anifrolumab shots in addition to standard therapy is safe and yields clinically meaningful benefits in moderate to severe systemic lupus erythematosus, according to the phase III TULIP-SC trial.

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

Lemon water found to have urate-lowering effect

Drinking lemon water regularly can be beneficial to people with gout and hyperuricemia, helping reduce serum urate levels and improve glomerular filtration rate, according to new research.

Lemon water found to have urate-lowering effect

09 Jan 2026

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

Endocan, miR-221 predict development of diabetic neuropathy

Endocan and miR-221 expression levels are significantly associated with development of neuropathy in patients with diabetes, indicating their potential role as biomarkers to diagnose diabetic peripheral neuropathy (DPN) at an early stage before the development of clinical manifestations, reports a study presented at ATTD-Asia 2025.

Endocan, miR-221 predict development of diabetic neuropathy

09 Jan 2026

T-DXd plus RT shows promise in management of metastatic breast cancer

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

T-DXd plus RT shows promise in management of metastatic breast cancer

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

In the treatment of acute ischaemic stroke in patients with recent direct oral anticoagulant (DOAC) use, intravenous thrombolysis appears to be safe and is associated with improvements in functional outcomes, according to a study.

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

IV iron lowers mortality risk in anaemics